vs

Side-by-side financial comparison of KAISER ALUMINUM CORP (KALU) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.

PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $929.0M, roughly 1.2× KAISER ALUMINUM CORP). KAISER ALUMINUM CORP runs the higher net margin — 3.0% vs -127.8%, a 130.8% gap on every dollar of revenue. On growth, KAISER ALUMINUM CORP posted the faster year-over-year revenue change (21.4% vs -2.5%). PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $-51.1M). Over the past eight quarters, KAISER ALUMINUM CORP's revenue compounded faster (12.2% CAGR vs 1.3%).

Kaiser Aluminum Corporation is an American aluminum producer. It is a spinoff from Kaiser Aluminum and Chemicals Corporation, which came to be when common stock was offered in Permanente Metals Corporation and Permanente Metals Corporation's name was changed to Kaiser Aluminum and Chemicals Corporation.

Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...

KALU vs PRGO — Head-to-Head

Bigger by revenue
PRGO
PRGO
1.2× larger
PRGO
$1.1B
$929.0M
KALU
Growing faster (revenue YoY)
KALU
KALU
+23.9% gap
KALU
21.4%
-2.5%
PRGO
Higher net margin
KALU
KALU
130.8% more per $
KALU
3.0%
-127.8%
PRGO
More free cash flow
PRGO
PRGO
$199.7M more FCF
PRGO
$148.6M
$-51.1M
KALU
Faster 2-yr revenue CAGR
KALU
KALU
Annualised
KALU
12.2%
1.3%
PRGO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
KALU
KALU
PRGO
PRGO
Revenue
$929.0M
$1.1B
Net Profit
$28.2M
$-1.4B
Gross Margin
13.3%
32.6%
Operating Margin
6.5%
-116.0%
Net Margin
3.0%
-127.8%
Revenue YoY
21.4%
-2.5%
Net Profit YoY
42.4%
-3093.9%
EPS (diluted)
$1.67
$-10.23

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KALU
KALU
PRGO
PRGO
Q4 25
$929.0M
$1.1B
Q3 25
$843.5M
$1.0B
Q2 25
$823.1M
$1.1B
Q1 25
$777.4M
$1.0B
Q4 24
$765.4M
$1.1B
Q3 24
$747.7M
$1.1B
Q2 24
$773.4M
$1.1B
Q1 24
$737.5M
$1.1B
Net Profit
KALU
KALU
PRGO
PRGO
Q4 25
$28.2M
$-1.4B
Q3 25
$39.5M
$7.5M
Q2 25
$23.2M
$-8.4M
Q1 25
$21.6M
$-6.4M
Q4 24
$19.8M
$-44.4M
Q3 24
$8.8M
$-21.0M
Q2 24
$18.9M
$-108.4M
Q1 24
$18.2M
$2.0M
Gross Margin
KALU
KALU
PRGO
PRGO
Q4 25
13.3%
32.6%
Q3 25
13.6%
36.1%
Q2 25
12.2%
34.4%
Q1 25
13.4%
37.6%
Q4 24
12.5%
33.9%
Q3 24
9.6%
37.2%
Q2 24
13.4%
37.0%
Q1 24
11.7%
33.1%
Operating Margin
KALU
KALU
PRGO
PRGO
Q4 25
6.5%
-116.0%
Q3 25
5.8%
7.0%
Q2 25
4.6%
4.3%
Q1 25
5.3%
4.5%
Q4 24
5.0%
10.0%
Q3 24
1.8%
7.4%
Q2 24
4.7%
-2.5%
Q1 24
3.3%
-5.1%
Net Margin
KALU
KALU
PRGO
PRGO
Q4 25
3.0%
-127.8%
Q3 25
4.7%
0.7%
Q2 25
2.8%
-0.8%
Q1 25
2.8%
-0.6%
Q4 24
2.6%
-3.9%
Q3 24
1.2%
-1.9%
Q2 24
2.4%
-10.2%
Q1 24
2.5%
0.2%
EPS (diluted)
KALU
KALU
PRGO
PRGO
Q4 25
$1.67
$-10.23
Q3 25
$2.38
$0.05
Q2 25
$1.41
$-0.06
Q1 25
$1.31
$-0.05
Q4 24
$1.21
$-0.32
Q3 24
$0.54
$-0.15
Q2 24
$1.15
$-0.79
Q1 24
$1.12
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KALU
KALU
PRGO
PRGO
Cash + ST InvestmentsLiquidity on hand
$7.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$826.1M
$2.9B
Total Assets
$2.6B
$8.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KALU
KALU
PRGO
PRGO
Q4 25
$7.0M
Q3 25
$17.2M
$432.1M
Q2 25
$13.1M
$454.2M
Q1 25
$21.3M
$409.9M
Q4 24
$18.4M
$558.8M
Q3 24
$45.7M
$1.5B
Q2 24
$70.4M
$542.8M
Q1 24
$101.6M
$658.5M
Stockholders' Equity
KALU
KALU
PRGO
PRGO
Q4 25
$826.1M
$2.9B
Q3 25
$806.1M
$4.4B
Q2 25
$776.0M
$4.5B
Q1 25
$756.8M
$4.4B
Q4 24
$743.1M
$4.3B
Q3 24
$729.4M
$4.6B
Q2 24
$727.6M
$4.5B
Q1 24
$714.7M
$4.7B
Total Assets
KALU
KALU
PRGO
PRGO
Q4 25
$2.6B
$8.5B
Q3 25
$2.6B
$10.1B
Q2 25
$2.5B
$10.1B
Q1 25
$2.4B
$9.8B
Q4 24
$2.4B
$9.6B
Q3 24
$2.3B
$11.2B
Q2 24
$2.3B
$10.4B
Q1 24
$2.3B
$10.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KALU
KALU
PRGO
PRGO
Operating Cash FlowLast quarter
$-20.6M
$175.4M
Free Cash FlowOCF − Capex
$-51.1M
$148.6M
FCF MarginFCF / Revenue
-5.5%
13.4%
Capex IntensityCapex / Revenue
3.3%
2.4%
Cash ConversionOCF / Net Profit
-0.73×
TTM Free Cash FlowTrailing 4 quarters
$-25.5M
$145.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KALU
KALU
PRGO
PRGO
Q4 25
$-20.6M
$175.4M
Q3 25
$59.1M
$51.7M
Q2 25
$15.9M
$75.9M
Q1 25
$57.0M
$-64.5M
Q4 24
$43.4M
$312.6M
Q3 24
$34.1M
$42.2M
Q2 24
$26.3M
$9.5M
Q1 24
$63.3M
$-1.4M
Free Cash Flow
KALU
KALU
PRGO
PRGO
Q4 25
$-51.1M
$148.6M
Q3 25
$34.5M
$29.8M
Q2 25
$-27.7M
$56.7M
Q1 25
$18.8M
$-90.0M
Q4 24
$-12.6M
$274.9M
Q3 24
$-17.0M
$15.1M
Q2 24
$-17.4M
$-18.9M
Q1 24
$33.3M
$-26.5M
FCF Margin
KALU
KALU
PRGO
PRGO
Q4 25
-5.5%
13.4%
Q3 25
4.1%
2.9%
Q2 25
-3.4%
5.4%
Q1 25
2.4%
-8.6%
Q4 24
-1.6%
24.2%
Q3 24
-2.3%
1.4%
Q2 24
-2.2%
-1.8%
Q1 24
4.5%
-2.4%
Capex Intensity
KALU
KALU
PRGO
PRGO
Q4 25
3.3%
2.4%
Q3 25
2.9%
2.1%
Q2 25
5.3%
1.8%
Q1 25
4.9%
2.4%
Q4 24
7.3%
3.3%
Q3 24
6.8%
2.5%
Q2 24
5.7%
2.7%
Q1 24
4.1%
2.3%
Cash Conversion
KALU
KALU
PRGO
PRGO
Q4 25
-0.73×
Q3 25
1.50×
6.89×
Q2 25
0.69×
Q1 25
2.64×
Q4 24
2.19×
Q3 24
3.88×
Q2 24
1.39×
Q1 24
3.48×
-0.70×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KALU
KALU

Packaging$440.6M47%
Aero Hs Products$213.0M23%
Transferred Over Time$200.2M22%
Automotive Extrusions$75.4M8%

PRGO
PRGO

Consumer Self Care Americas$697.0M63%
Digestive Health$123.9M11%
Nutrition$108.3M10%
Healthy Lifestyle$94.8M9%
Pain And Sleep Aids$87.1M8%

Related Comparisons